SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending with retail traders actively discussing price targets and potential for a short squeeze. Despite recent earnings and raised guidance, some express concern over market conditions and volatility. Optimistic investors point to institutional ownership, AI momentum, and potential government reopening as catalysts for a rebound.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending amid discussions about its strategic acquisition of Sentrycs, a counter-drone technology company, and its potential impact on revenue. Community members are debating the company's valuation and growth prospects within the defense and security sectors, as well as upcoming earnings and the potential for government contracts.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as investors flock to privacy coins, with community members discussing its potential to reach $1,000 and comparing it to Bitcoin's early days. A recent Coindesk article has added fuel to the fire, while some traders are pointing to a pullback. The coin's limited supply and focus on shielded transactions are key talking points.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk Corp. is trending due to optimism around its potential in the inference market and high-bandwidth flash memory, with community members drawing comparisons to past high-growth tech stories. Despite some bearish sentiment focused on profitability, bullish traders are pointing to future earnings estimates and significant volume spikes as potential catalysts. The stock's parabolic year-to-date performance and analyst upgrades are fueling FOMO, while others caution about overvaluation and potential manipulation.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy`s Co

Wendy's ($WEN) is trending as community members discuss its recent earnings beat and subsequent stock reversal, closing lower despite initial gains. Investors are weighing the impact of store closures and a turnaround plan amidst leadership uncertainty, while some speculate on the potential for a short squeeze or buyout.

Peanut the Squirrel Markets

Peanut the Squirrel Markets ($PNUT) is surging, driven by community enthusiasm and speculative momentum reminiscent of other meme coins. Community members are actively discussing potential price targets and noting high trading volume, with some drawing comparisons to established meme coins and anticipating further gains. The coin's recent price action and increased visibility are fueling the current buzz.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer's stock is active amid an ongoing bidding war with Novo Nordisk for Metsera, a company focused on obesity drugs, with Pfizer filing lawsuits to challenge Novo's acquisition. The community is discussing the implications of this battle, Pfizer's overall strategy in the weight loss market, and whether the company is overpaying for potential acquisitions. Additionally, the stock's dividend and recent earnings are focal points of conversation.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending as the company announced a collaboration with Talen Energy to develop energy storage for AI infrastructure, along with a new supply agreement and expansion plans. Community members are discussing the potential impact of these developments, especially the partnership with a company that powers Amazon's data centers. Some are also focused on the company's short interest and potential for a squeeze.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending amidst an ongoing bidding war with Pfizer for Metsera and speculation around upcoming announcements regarding GLP-1 drug pricing and FDA approval for an oral version of Wegovy. Community discussions revolve around the potential impact of a deal with the Trump administration on drug prices and market access, as well as concerns about company management and strategic direction given these developments.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to discussions around small caps potentially outperforming inflated tech stocks, as traders debate whether the recent pullback presents a buying opportunity or signals further declines. Community members are actively analyzing technical indicators and potential market catalysts like government reopenings and tariff decisions. Some traders are also pointing to high valuations and unprofitable companies within the IWM as reasons for caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Lynx1 Capital Management LP boosted its stake in Neuphoria Therapeutics by acquiring 639,110 shares.</li><li>The shares were bought at prices ranging from $4.96 to $5.20, with an average cost of $5.137 per share.</li><li>On Monday, Nuphoria&nbsp;announced a comprehensive strategic review of its business operations and pipeline.</li></ul>Neuphoria Therapeutics Inc. (NEUP) stock drew heightened attention from retail investors after prominent investor Lynx1 Capital Management LP increased its stake by acquiring 639,110 shares.The share purchase, made on October 21, was disclosed in a Securities and Exchange Commission (SEC)&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1191070/000090266425004536/xslF345X05/ownership.xml">filing</a>.&nbsp;<h2 class="st-heading-2">Pricing Details&nbsp;</h2>The shares were bought at prices ranging from $4.96 to $5.20, with an average cost of $5.137 per share. In total, Lynx1 Capital spent $3.3 million to expand its position.&nbsp;Following this acquisition, the investment firm now&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1191070/000090266425004537/xslSCHEDULE_13D_X01/primary_doc.xml">controls&nbsp;</a>875,328 shares of Neuphoria Therapeutics. The transaction highlights growing investor confidence in Neuphoria’s pipeline and market potential.<a href="https://stocktwits.com/symbol/NEUP">Neuphoria Therapeutics’ stock</a> traded over 64% higher on Friday morning and was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.Neuphoria focuses on creating treatments for neuropsychiatric conditions. Its main drug candidate, BNC210, is an anti-anxiety therapy designed to rebalance brain neurotransmitters and deliver fast relief from anxiety and stress without causing sedation, cognitive issues, or dependency.AFFIRM-1 Phase 3 Trial Update&nbsp;On Monday, Neuphoria said its late-stage clinical trial for the drug BNC210 did not meet the main or secondary goals in treating patients with social anxiety disorder (SAD). The company announced the findings from its Phase 3 AFFIRM-1 study, which measured changes in anxiety levels using the Subjective Units of Distress Scale (SUDS) during a public speaking challenge.However, building on earlier positive data from studies involving chronic daily dosing, Neuphoria said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD).&nbsp;The company had also announced a comprehensive strategic review of its business operations and pipeline, with an update expected by the end of 2025.Neuphoria stock has gained over 78% in 2025 and over 41% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-neup-stock-surge-64-today/cLGJpuSR3tJ">Why Did NEUP Stock Surge 64% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pfizer scientist Larry James works with Western blots for a schizophrenia cognition deficits project in the neuroscience & pain lab.

Why Did NEUP Stock Surge 64% Today?

Lynx1 Capital Management LP boosted its stake in Neuphoria Therapeutics by acquiring 639,110 shares.

Equity

Shares of Neuphoria Therapeutics Inc. soared more than 11% in premarket trading on Wednesday, propelling the micro-cap biotech stock into the top 10 trending symbols on Stocktwits.&nbsp;The company is set to receive a $15 million milestone payment from Merck, triggered by the latter's initiation of a Phase 2 clinical trial to assess the safety and efficacy of MK-1167, an experimental drug for Alzheimer's disease dementia.&nbsp;This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments, along with royalties on any licensed medicines.Investors on the platform have expressed enthusiasm, with one user speculating that the stock could reach double digits soon, while another suggested it should ideally trade at more than triple its current levels.<stembedurl>https://stocktwits.com/Tigerphoenix/message/603914417</stembedurl><stembedurl>https://stocktwits.com/Realtrader77/message/603914418</stembedurl>Neuphoria, which has a market cap of just over $7.2 million, saw an 86% jump in following over the past month and a 1,200% increase in message volume on Stocktwits in the last week.&nbsp;Earlier in the month, H.C. Wainwright raised its price target on Neuphoria to $21 from $8, maintaining a 'Buy' rating.&nbsp;The research firm said its valuation argument was based on the company's progress with its broad-spectrum anti-anxiety therapeutic, BNC210.&nbsp;According to Koyfin data, at the end of the September quarter, Neuphoria had approximately $8 million in cash and investments and total debt under $220,000.&nbsp;<a href="https://stocktwits.com/symbol/NEUP">Neuphoria's stock</a> has lost more than 63% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

NEUP
Neuphoria Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NEUP News

NEUPNeuphoria Therapeutics Inc.